Inhibrx Biosciences, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | $<0.1 | $<0.1 | $<0.1 | — |
| Operating income | -$0.1 | -$0.3 | -$0.2 | — |
| Net income | -$0.1 | $1.7 | -$0.2 | — |
| Cash Flow Statement | ||||
| Free cash flow | -$0.1 | -$0.2 | -$0.2 | — |
Shares outstanding 14.7M · Free float 62.9%
Annual filing data through FY ended December 31, 2025; float as of September 14, 2026.